CCL19 and breast cancer: Despite this, in the TCGA breast cancer patient cohort, CCL19 expression in tumor tissues was associated with increased overall and relapse-free survival (HR for the last tertile vs. first tertile = 0.58, 95% CI = 0.35–0.95).